Pembrolizumab Shows Further Promise for Melanoma
In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
Tackling Drug Resistance
Researchers are studing new ways to keep treatments working longer.
by Stephen Ornes
Living in the Here and Now
A metastatic melanoma survivor is hopeful but realistic as new treatments become available.
by Jenny Song
Cancer Immunotherapies Continue to Make Headway
Drugs that harness the power of the immune system gain new approvals.
by Alexandra Goho
Knowing Her Options
When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors.
by Melissa Davlin
Keeping Sight of Hope
A survivor keeps an eye on what's ahead after a rare cancer diagnosis.
by Sue Russell
Boosting Defenses Against Cancer
Q&A with immunologist James P. Allison, Memorial Sloan-Kettering Cancer Center, New York City.
by Ingfei Chen